Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Tucatinib

871ed1ec-b440-53ae-a3c4-f92c6c4c534d · FDA Approved · targets ERBB2_HER2

Tucatinib

MeasuredReference

Tucatinib targets JAK1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

JAK1

Top hallmarks

  • tumor promoting inflammation1.5k
  • immune evasion806
  • evading apoptosis770

Top pathways disrupted

No pathway data.

Resistance landscape — Tucatinib

MeasuredReference

No variant annotations found on Tucatinib's top targets.

No variant annotations on Tucatinib's top targets.
Open in new tab